Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias

2006 ◽  
Vol 44 (7) ◽  
Author(s):  
Stefano Zoccolella ◽  
Paolo Lamberti ◽  
Giovanni Iliceto ◽  
Claudia Dell'Aquila ◽  
Cosimo Diroma ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Plasma Homocysteine ◽  
Elevated Plasma

AbstractClin Chem Lab Med 2006;44:863–6.

Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions

2005 ◽  
Vol 43 (10) ◽  
Author(s):  
Stefano Zoccolella ◽  
Paolo Lamberti ◽  
Giovanni Iliceto ◽  
Cosimo Diroma ◽  
Elio Armenise ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Plasma Homocysteine ◽  
Vitamin B ◽  
Elevated Plasma ◽  
Cognitive Dysfunctions ◽  
The Relationship ◽  
Late Stages

AbstractElevated plasma homocysteine (Hcy) concentrations are associated with Alzheimer's disease and vascular dementia. Several recent reports have indicated that L-dopa treatment is an acquired cause of hyperhomo-cysteinemia. Despite the fact that a large proportion of Parkinson's disease (PD) patients develop cognitive dysfunctions or dementia, particularly in the late stages of the illness and after long-term L-dopa treatment, the relationship between Hcy and dementia in PD has not been fully investigated. The aim of this study was to evaluate plasma Hcy levels in a group of L-dopa-treated PD patients with cognitive impairment and to elucidate a possible role of Hcy in the development of cognitive dysfunctions in PD. We compared Hcy, vitamin B

Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review

2007 ◽  
Vol 45 (12) ◽  
Author(s):  
Stefano Zoccolella ◽  
Giovanni Iliceto ◽  
Michele deMari ◽  
Paolo Livrea ◽  
Paolo Lamberti
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Plasma Homocysteine ◽  
B Vitamins ◽  
Elevated Plasma ◽  
Therapeutic Approaches ◽  
Cytotoxic Effects ◽  
Comt Inhibitors ◽  
Clinical Correlations ◽  
Diet Supplementation

AbstractIn recent years, L-Dopa treatment has been indicated as an acquired cause of hyperhomocysteinemia (HHcy). The mechanism underlying L-Dopa-related HHcy is the O-methylation of the drug catalyzed by the enzyme catechol-O-methyltransferase (COMT). Folate and cobalamin status also influences the effects of L-Dopa on plasma homocysteine (Hcy) levels. Although clinical correlations of HHcy in Parkinson's disease still remain uncertain, management of elevated plasma Hcy levels has been advocated, due to multiple cytotoxic effects of Hcy on neurons. This review summarizes data available in the literature concerning the two main therapeutic approaches to L-Dopa-related HHcy (use of COMT inhibitors or B vitamins diet supplementation).Clin Chem Lab Med 2007;45:1607–13.

Effect of entacapone on plasma homocysteine levels in Parkinson’s disease patients

2010 ◽  
Vol 31 (5) ◽  
pp. 565-569 ◽  
Author(s):  
Martin Nevrly ◽  
Petr Kanovsky ◽  
Hana Vranova ◽  
Katerina Langova ◽  
Petr Hlustik
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Plasma Homocysteine

Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease

2004 ◽  
Vol 19 (12) ◽  
pp. 1403-1408 ◽  
Author(s):  
Padraig E. O'Suilleabhain ◽  
Teodoro Bottiglieri ◽  
Richard B. Dewey ◽  
Shailja Sharma ◽  
Ramon Diaz-Arrastia
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Plasma Homocysteine ◽  
Modest Increase
Sign in / Sign up

Export Citation Format

Share Document